We are live on ! Find out more
AERI

Aerie Pharmaceuticals

Delisted

AERI was delisted on the 18th of November, 2022.

76 hedge funds and large institutions have $410M invested in Aerie Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 36 increasing their positions, 7 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

414% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 7

200% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 8

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

27% more funds holding

Funds holding: 6076 (+16)

4% more capital invested

Capital invested by funds: $392M → $410M (+$17.4M)

Holders
76
Holders Change
+16
Holders Change %
+26.67%
% of All Funds
2.2%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
24
Increased
36
Reduced
7
Closed
8
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Manulife (Manufacturers Life Insurance)
76
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$152 -$4.28K -217 -3%
CS
77
Credit Suisse
Switzerland
-$277K -11,175 Closed
Jane Street
78
Jane Street
New York
-$231K -9,338 Closed
KeyBank National Association
79
KeyBank National Association
Ohio
-$210K -8,480 Closed
TRCT
80
Tower Research Capital (TRC)
New York
-$52K -2,080 Closed
VFA
81
Virtus Fund Advisers
Connecticut
-$22K -896 Closed
BJ
82
BlackRock Japan
Japan
-$13K -531 Closed
PNC Financial Services Group
83
PNC Financial Services Group
Pennsylvania
-$12K -500 Closed
Bank of Montreal
84
Bank of Montreal
Ontario, Canada
-$5K -200 Closed

AERI Hedge Fund Activity: Q3 2014 in Review

76 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q3 2014, worth a combined $410M — up 4.4% from $392M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new AERI positions and 8 closed out — a net gain of 16 holders — while 36 added to existing stakes and 7 trimmed.

The largest buyer was Deerfield Management, adding an estimated $19.2M. The largest seller was TPG Group Holdings (SBS) Advisors, cutting an estimated $19.7M.

  • 76 institutional investors held Aerie Pharmaceuticals (AERI) as of Q3 2014, up from 60 in Q2 2014.
  • Funds reported $410M of Aerie Pharmaceuticals stock for Q3 2014, up 4.4% quarter-over-quarter.
  • 24 funds opened new Aerie Pharmaceuticals positions in Q3 2014 and 8 closed out, a net change of +16 holders.
  • The largest Aerie Pharmaceuticals buyer in Q3 2014 was Deerfield Management, an estimated $19.2M added.
  • The largest Aerie Pharmaceuticals seller in Q3 2014 was TPG Group Holdings (SBS) Advisors, an estimated $19.7M sold.

Based on aggregated 13F filings for Q3 2014.